Venus Concept

Venus Concept, Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related practice enhancement services. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Venus Concept surpasses revenue expectations in Q1 2024 earnings call

Venus Concept's Q1 2024 performance showed resilience with revenue exceeding expectations despite challenges. Strategic initiatives to exit unprofitable markets and focus on cash system sales led to improved financial metrics. The company's progress in key initiatives and financial improvements demonstrate a commitment to long-term growth and stability.

Venus Concept reports mixed Q3 results, eyes growth opportunities

Venus Concept faced revenue challenges in Q3 2024, but saw growth in distributor sales and progress in restructuring efforts. Despite financial setbacks, the company is optimistic about new product launches, regulatory clearances, and debt reduction strategies. Analyst interest remains high in revenue mix, new product launches, market strengths, and debt management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Venus Concept Inc. (VERO) CEO Domenic Serafino on Q4 2019 Results - Earnings Call Transcript

TORONTO, March  18, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it entered into a definitive agreement for the sale of shares of its common stock, Series A convertible preferred stock and warrants to purchase common stock in a private placement to a group of investors, including EW Healthcare Partners, HealthQuest Capital and SEDCO Capital. The private placement is expected to result in gross proceeds to the Company of approximately $22.25 million, before deducting placement agent fees and other offering expenses.

Venus Concept Inc. Announces $22.25 Million Equity Financing

Chad A. Zaring, Appointed Chief Commercial Officer Chad A. Zaring, Appointed Chief Commercial Officer

Venus Concept Expands Executive Team

TORONTO, Feb.  14, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received CE Mark approval to market Venus Bliss for non-invasive lipolysis of the abdomen and flanks, skin tightening, circumferential reduction and cellulite reduction and a medical device license issued by Health Canada to market NeoGraft 2.0 for hair restoration.

Venus Concept Inc. Announces New Regulatory Clearances

TORONTO, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced preliminary unaudited revenue results for the three months and twelve months ended December 31, 2019 and introduced revenue guidance expectations for the twelve months ended December 31, 2020. The Company notes that the GAAP revenue results provided give effect to the business combination between Restoration Robotics, Inc. and Venus Concept Ltd., which closed on November 7, 2019. 

Venus Concept Announces Preliminary Fourth Quarter and Fiscal Year 2019 Revenue Results; Introduces Fiscal Year 2020 Revenue Guidance

News for Venus Concept Stock (VERO)